Gilead Sciences: Sure, It’s Hep-C But It’s Not Just Hep-C
July 27, 2015 at 17:16 PM EDT
In less than 24 hours, Gilead Sciences (GILD) will be reporting its second-quarter financial results. Evercore ISI’s Mark Schoenebaum tells investors what to expect: IMS scripts for Gilead’s HepC Harvoni/Sovaldi started relatively slow decline after peaking at the end of the 1st quarter but still are well above the previous peak of Sovaldi scripts in 2014. [...]
